Welcome to the Treating CD30+ Lymphoma Platform

Welcome, this website is intended for healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

5-year follow-up of the pivotal Phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

martin_hutchings_cpenhagenv02 (1)